Last update: Jan. 15, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
R01AA05; R01AB07; S01GA04 is Oxymetazoline Hydrochloride in ATC Code/s.
Is written in other languages:R01AA05; R01AB07; S01GA04 is also known as
R01AA05; R01AB07; S01GA04 belongs to these groups or families:
Main tradenames from several countries containing R01AA05; R01AB07; S01GA04 in its composition:
Variable | Value | Unit |
---|---|---|
Molecular weight | 297 | daltons |
Protein Binding | 57 | % |
pKa | 10,9 | - |
Tmax | 0,1 - 0,2 | hours |
T1/2 | 5,2 | hours |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A sympathomimetic with alpha-adrenergic activity. It has a vasoconstrictor effect which reduces mucosal swelling and congestion.
Topical use via nasal spray (twice a day) or ophthalmological (3-4 times a day).
It is also used in face cream to treat rosacea (Kuang 2018) and, mixed with local anesthetics, in dental anesthesia.
Since the last update we have not found published data in relation to breastfeeding.
The small dose and low plasma absorption of most topical nasal, dermal or ophthalmological preparations make transfer into breastmilk in significant amounts unlikely.
Recorded plasma concentrations of oxymetazoline are low and their systemic effects are not clinically significant with the usual doses (Cartabuke 2019, Kuang 2018, Cacek 2017, Giannakopoulos 2012), so significant concentrations in milk are not expected.
Do not exceed the recommended dose and time periods in order to avoid undesirable side effects and the possible decrease in milk production cited by some authors (Nice 2000), but not proven in practice.
Expert authors consider the use of this medication to be safe and probably compatible during breastfeeding (Hale 2019, Briggs 2017, Anderson 2000).
Ophthalmic administration is fully compatible with breastfeeding. Absorption can be minimized by pressing on the tear duct (medial canthus of the eye) with your finger for 1 minute.
Some authors consider decongestant drugs administered orally and nasally to be non-essential medications, to be avoided in general, not only during breastfeeding, since they expose patients to serious risks (cardiovascular, neurological and intestinal) for the treatment of benign disorders such as nasal obstruction, which usually evolves favourably in a few days without medication (Prescrire 2018).